T1	Condition-Name 50 52	UC
T2	Eq-Operator 57 65	at least
A1	Eq-Operator-Value T2 GTEQ
T3	Eq-Comparison 57 74	at least 3 months
T4	Eq-Value 66 67	3
T5	Eq-Temporal-Unit 68 74	months
A2	Eq-Temporal-Unit-Value T5 month
T6	Temporal-Connection 75 80	prior
T7	Temporal-Connection 75 83	prior to
T8	Study 84 93	screening
T9	And 96 100	with
T10	Eq-Value 127 129	15
T11	Eq-Unit 130 132	cm
T12	Observation-Name 203 211	response
T13	Procedure 223 232	treatment
T14	Drug-Name 238 253	oral mesalamine
T15	Eq-Operator 254 255	≥
A3	Eq-Operator-Value T15 GTEQ
T16	Eq-Comparison 254 267	≥ 2.4 g / day
T17	Eq-Value 256 259	2.4
T18	Eq-Unit 260 261	g
T19	Eq-Temporal-Unit 264 267	day
A4	Eq-Temporal-Unit-Value T19 day
T20	Eq-Operator 272 273	≥
A5	Eq-Operator-Value T20 GTEQ
T21	Eq-Comparison 272 281	≥ 4 weeks
T22	Eq-Value 274 275	4
T23	Eq-Temporal-Unit 276 281	weeks
A6	Eq-Temporal-Unit-Value T23 week
T24	Assertion 329 337	Possible
T25	Condition-Name 364 380	Crohn 's Disease
T26	Or 381 383	or
T27	Or 440 442	or
T28	Eq-Temporal-Period 450 455	prior
A7	Eq-Temporal-Period-Value T28 past
T29	Procedure 456 465	treatment
T30	Condition-Name 470 472	UC
T31	Drug-Name 530 542	cyclosporine
T32	Drug-Name 545 556	tofacitinib
T33	Drug-Name 559 580	mycophenolate mofetil
T34	Drug-Name 583 592	sirolimus
T35	Drug-Name 595 604	rapamycin
T36	Drug-Name 609 620	thalidomide
T37	Drug-Name 623 633	tacrolimus
T38	Drug-Name 636 644	FK - 506
T39	Drug-Name 652 661	biologics
T40	Drug-Name 671 696	TNF - alpha - antagonists
T41	Drug-Name 699 724	anti - integrin therapies
T42	Drug 730 736	agents
T43	Or 755 757	or
T44	Eq-Temporal-Period 864 871	History
A8	Eq-Temporal-Period-Value T44 past
T45	Eq-Temporal-Period 875 880	prior
A9	Eq-Temporal-Period-Value T45 past
T46	Procedure-Name 881 902	surgical intervention
T47	Eq-Temporal-Period 979 984	Prior
A10	Eq-Temporal-Period-Value T47 past
T48	Modifier 1002 1016	cardiovascular
T49	Modifier 1019 1024	renal
T50	Modifier 1027 1034	hepatic
T51	Modifier 1037 1046	endocrine
T52	Modifier 1049 1059	infectious
T53	Modifier 1062 1075	hematological
T54	Modifier 1078 1087	oncologic
T55	Modifier 1090 1095	neuro
T56	Modifier 1090 1109	neuro - psychiatric
T57	Or 1110 1112	or
T58	Modifier 1113 1130	immune - mediated
T59	Condition-Name 1131 1139	disorder
T60	Procedure 1281 1290	Treatment
T61	Other 1300 1305	other
T62	Study 1306 1321	investigational
T63	Drug 1322 1327	drugs
T64	Condition 1389 1398	condition
T65	Or 1399 1401	or
T66	Condition 1410 1419	situation
T67	Severity 1498 1509	significant
A11	Severity-Value T67 severe
T68	Risk 1510 1514	risk
T69	Assertion 1517 1520	may
T70	Stability 1521 1529	confound
A12	Stability-Value T70 change
T71	Study 1534 1539	study
T72	Unknown 223 232	treatment
T73	Unknown 238 253	oral mesalamine
R1	Using Arg1:T72 Arg2:T73
T74	Unknown 1280 1280	
T75	Unknown 1322 1327	drugs
R2	Using Arg1:T74 Arg2:T75
T76	Unknown 1281 1290	Treatment
T77	Unknown 1322 1327	drugs
R3	Using Arg1:T76 Arg2:T77